TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05932615

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Navitor Transcatheter Aortic Valve Implantation (TAVI) System
Description: TAVI for relief of calcific aortic stenosis in patients with symptomatic heart disease who are at intermediate or low risk for open surgical therapy.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Any Commercially Available Transcatheter Aortic Valve (CAV) System
Description: TAVI for relief of calcific aortic stenosis in patients with symptomatic heart disease who are at intermediate or low risk for open surgical therapy.
Study: NCT06303336

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NMES with Dynamic Bracing
Description: The group will receive NMES along with dynamic bracing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NMES without Dynamic Bracing
Description: The participants will receive NMES on the lower extremity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic Bracing Only
Description: This group will receive dynamic bracing only on the lower limb.
Study: NCT05574478

Intervention type: BEHAVIORAL
Intervention: Patients and Caregivers Qualitative Interview
Description: Interviews will be conducted by experienced qualitative researchers from the UNC Connected Health for Applications \& Interventions (CHAI) Core. The interview will be conducted over the phone or secure videoconferencing. The interview will be conducted in a semi-structured fashion using an interview guide. However, because the purpose of this semi-structured qualitative interview study is to determine which themes participants identify as important, the exact content of each interview will differ, and the interview guide will be modified as additional interviews are conducted. Interviews will be audio recorded with concurrent notetaking by the interviewer.
Study: NCT05106881

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Training with Gait Enhancing and Motivating System (GEMS-H) Robot
Description: Training consists of 15 minutes task-specific training and 30 minutes functional gait training on varied environments with device.
Study: NCT06090604

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity gait training in a balance challenging Movement amplification environment
Description: For Aim 2, each participant will engage in ten 45-min high-intensity gait training sessions performed in a Movement Amplification Environment (MAE). Training sessions will occur 2x/week and led by a licensed Physical Therapist. The goal of each training session is to achieve 40-min of stepping practice within a targeted range of heart rate (HR) of 70 to 80% of estimated age-predicted HR max and perceived excursion (RPE) in a MAE. Each session will begin and end with a 2.5-min warm-up and cool down, with 40-min of training using two 10-min Speed-training blocks and two 10-min Balance-training blocks. Balance training activities will include lateral maneuvers, head turns, obstacle negotiation, and backward walking. The MAE gain, training speeds and balance activities will be progressively increased within and across sessions to challenge the participant.
Study: NCT06296017

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Extracorporeal Shock Wave Therapy
Description: Extracorporeal Shock Wave Therapy (ESWT for short) application will be performed on A1 pulley at 15 Hz, 1000 shock wave impulses, and 2.0 bar level, for a total of 5 sessions, one week apart.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trigger Finger Splint
Description: A trigger finger splint that immobilizes the MCF joint will be recommended for the splint treatment group. The patient will be asked to use this splint throughout the day for 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy+ Trigger Finger Splint
Description: Extracorporeal Shock Wave Therapy (ESWT for short) application will be performed on A1 pulley at 15 Hz, 1000 shock wave impulses, and 2.0 bar level, for a total of 5 sessions, one week apart. Also, A trigger finger splint that immobilizes the MCF joint will be recommended.
Study: NCT05790889

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Rabies vaccine
Description: Vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Rabies vaccine
Description: Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RH5.1 10μg adjuvated with 50μg Matrix-M
Description: Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RH5.1 10μg adjuvated with 50μg Matrix-M
Description: Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RH5.2 5μg adjuvated with 50μg Matrix-M
Description: Vaccine
Study: NCT05970575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NE3107
Description: Participants will take 20mg twice daily (BID) approximately 12 hours apart. The dose will be stable the duration of the study intervention (6 months)
Study: NCT04986202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4831
Description: AZD4831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4831
Description: AZD4831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4831
Description: AZD4831

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06171958

Intervention type: DRUG
Intervention: Iodine-containing Contrast Media
Description: Patients will receive or not receive ICM depending on their medical need.
Study: NCT05817903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: Axitinib will be started at the standard dose of 5 mg BID until progression of disease, unacceptable toxicity, patient' or physician' decision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered at a flat dose of 480 mg IV every four weeks until progression of disease, unacceptable toxicity, patient' or physician' decision

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Nivolumab will be administered at a flat dose of 480 mg IV every four weeks until progression of disease, unacceptable toxicity, patient' or physician' decision
Study: NCT04803877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib 40 MG
Description: For subjects age 18 and older, Regorafenib will be administered as 80mg oral once daily on Cycle 1, Days 1-7 and then escalated to 120 mg once daily for Cycle 1, Days 8-21 if no Grade 2 or above regorafenib adverse events occur. For subsequent cycles, the highest tolerated dose will be taken once daily on days 1-21 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib 20MG
Description: For subjects younger than 18 years, Regorafenib will be administered as 60mg/m2/dose (rounded to the nearest 20mg, maximum dose of 80mg) once daily for Cycle 1, Days 8-21 if no Grade 2 or above regorafenib-related adverse events occur. For subsequent cycles, the highest tolerated dose will be taken once daily on days 1-21 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: For subjects age 18 and older, Nivolumab will be administered at 480mg IV over 30 min every 28 days.~For subjects younger than 18 years, Nivolumab 3mg/kg (maximum dose 240mg) will be administered IV over 30 minutes on day 1 and 15 of each 28-day cycle.
Study: NCT04740983

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heliotherapy (a sole sun-bathing)
Description: 16-week heliotherapy regimen based on the predicted anti psoriasis effective irradiance values.
Study: NCT00000928

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group counseling intervention
Description: Participants will engage in a multi-session group-based condom promotion program for approximately 12 months
Study: NCT05868603

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remineralization gel
Description: Remineralization gel

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remineralization gel
Description: Remineralization gel
Study: NCT06217939

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Early hydrocortisone
Description: For the Early Hydrocortisone group, 50 mg of hydrocortisone in 10 ml of normal saline will be given as an intravenous bolus, then 200 mg of hydrocortisone in 100 ml of normal saline will be given as continuous intravenous infusion in 24 hours for 2 consecutive days (total 250 mg in day 1 and 200 mg in day 2).~After completion of the study drugs for 2 days, the study drug will be discontinued without tapering.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline placebo
Description: For the Standard Care group, a bolus of 10 ml of normal saline will be given, then 100 ml of normal saline will be given as continuous intravenous infusion in 24 hours for 2 consecutive days as a sham control.~After completion of the study drugs for 2 days, the study drug will be discontinued without tapering.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open-label hydrocortisone
Description: An open-label 50 mg of hydrocortisone given as an intravenous bolus followed by intravenous hydrocortisone 200 mg/day given as continuous infusion or divided bolus administration is suggested to be commenced in both study arms if the hemodynamic goal of the patient is not reached despite the dose of norepinephrine or epinephrine ≥ 0.25 mcg/kg/min at least 4 hours after the initiation of the vasopressors as recommended by the guideline. The study drug in each arm will be discontinued once an open-label hydrocortisone is initiated. Capillary or venous blood glucose will be tested at least every 6 hours for 2 days then at least once daily or more as appropriate for the first 7 days as a part of the study protocol.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Open-label hydrocortisone
Description: An open-label 50 mg of hydrocortisone given as an intravenous bolus followed by intravenous hydrocortisone 200 mg/day given as continuous infusion or divided bolus administration is suggested to be commenced in both study arms if the hemodynamic goal of the patient is not reached despite the dose of norepinephrine or epinephrine ≥ 0.25 mcg/kg/min at least 4 hours after the initiation of the vasopressors as recommended by the guideline. The study drug in each arm will be discontinued once an open-label hydrocortisone is initiated. Capillary or venous blood glucose will be tested at least every 6 hours for 2 days then at least once daily or more as appropriate for the first 7 days as a part of the study protocol.
Study: NCT05220722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-101
Description: SD-101 doses will be delivered via HAI using the PEDD method of administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: During Phase 1b, Cohort B, pembrolizumab will be administered together with SD-101.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: During Phase 1b, Cohort C, nivolumab will be administered together with ipilimumab and SD-101.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: During Phase 1b, Cohort C, ipilimumab will be administered together with nivolumab and SD-101.
Study: NCT05258240

Intervention type: OTHER
Group type: OTHER
Intervention: Virtual Reality
Description: Virtual reality workout enhances balance control, self-reported balance and mental stability in healthy and stable adults. Sensory-based exercise and the response to visual acuity can increase the patient's ability to maintain their body in a stable position.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional Physical Therapy
Description: Postural training, standing, walking, and walking activities are included in the conventional physical therapy in domain of balance exercise training programs. These activities are usually boring and tedious because these exercises are repeated many times.
Study: NCT06297187

Intervention type: DEVICE
Intervention: CUSA (Cavitronic Ultrasonic Surgical Aspirator)
Description: CUSA® Excel and CUSA® Clarity Ultrasonic Surgical Aspirator Systems are indicated for use in the surgical procedures where fragmentation, emulsification and aspiration of soft and hard tissue is desirable.

Intervention type: DEVICE
Intervention: CUSA (Cavitronic Ultrasonic Surgical Aspirator)
Description: CUSA® Excel and CUSA® Clarity Ultrasonic Surgical Aspirator Systems are indicated for use in the surgical procedures where fragmentation, emulsification and aspiration of soft and hard tissue is desirable.
Study: NCT06285487

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Program
Description: Participants in both arms will receive 6 weeks of T2D-IPT or 6 weeks of T2DEd.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Program
Description: Participants in both arms will receive 6 weeks of T2D-IPT or 6 weeks of T2DEd.
Study: NCT05241379

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amber UI System
Description: The implantable components of the Amber UI system consist of an implantable pulse generator (Picostim Amber IPG), 2 electrode leads with anchoring system
Study: NCT06421857

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: suturing
Description: laparoscopic cystectomy for endometrioma and hemostasis was done using suturing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bipolar electrocoagulation
Description: laparoscopic cystectomy for endometrioma and hemostasis was done bipolar electrocoagulation
Study: NCT06325059

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study of renal progenitors
Description: Evaluation of the role of renal progenitors in pathogenesis and mechanisms of disease progression in kidney biopsies performed for diagnostic purposes
Study: NCT06387823

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sivelestat sodium
Description: Sevilastat sodium 4.8 mg/kg/d IV continuous infusion for 14 days or ICU length of stay (within 14 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 10 mg IV once a day for 5 days or until extubation (within 5 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sivelestat sodium placebo
Description: Sivelestat sodium placebo 4.8 mg/kg/d IV continuous infusion for 14 days or ICU length of stay (within 14 days)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sivelestat sodium placebo
Description: Sivelestat sodium placebo 4.8 mg/kg/d IV continuous infusion for 14 days or ICU length of stay (within 14 days)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone placebo
Description: Dexamethasone placebo 10 mg IV once a day for 5 days or until extubation (within 5 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone placebo
Description: Dexamethasone placebo 10 mg IV once a day for 5 days or until extubation (within 5 days)
Study: NCT05806463

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mother's Time
Description: Mother's Time is an evidence-based cognitive behavioral therapy (CBT) tool designed to support postpartum women experiencing mild to moderate symptoms of stress, depression, or anxiety. The intervention is designed for use by Ethiopian community health workers (CHWs) and includes CBT exercises and discussion on topics relating to family planning, such as planning for the future, speaking to the husband, and considering potential side effects.
Study: NCT04955171

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BEOVU intravitreal injection
Description: BEOVU intravitreal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BEOVU intravitreal injection
Description: BEOVU intravitreal injection
Study: NCT06211608

Intervention type: DIAGNOSTIC_TEST
Intervention: Two-dimensional and three-dimensional ultrasound of the female reproductive organ
Description: Two-dimensional and three-dimensional ultrasound of the female reproductive organ using a Samsung WS80A or Samsung HERA W10 ultrasound device with a transvaginal or transabdominal transducer

Intervention type: DIAGNOSTIC_TEST
Intervention: Two-dimensional and three-dimensional ultrasound of the female reproductive organ
Description: Two-dimensional and three-dimensional ultrasound of the female reproductive organ using a Samsung WS80A or Samsung HERA W10 ultrasound device with a transvaginal or transabdominal transducer
Study: NCT05376384

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound parameters
Description: Annotation of ultrasonographic features of ovarian cyst. The parts examined are size, laterality, content, margins, and color score.

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound parameters
Description: Annotation of ultrasonographic features of ovarian cyst. The parts examined are size, laterality, content, margins, and color score.

Intervention type: PROCEDURE
Intervention: intraoperative parameters
Description: Annotation of intraoperative features of ovarian cyst. The characteristics under review are: surgeon experience, previous surgery, adhesions, and uterine manipulator use

Intervention type: PROCEDURE
Intervention: intraoperative parameters
Description: Annotation of intraoperative features of ovarian cyst. The characteristics under review are: surgeon experience, previous surgery, adhesions, and uterine manipulator use
Study: NCT05096624

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DD-TENS system
Description: Use of DD-TENS system

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gold Standard
Description: Gold standard

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Digital Denture system
Description: Use of Digital Denture system
Study: NCT05114824

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy
Description: The intervention is based on a mixed MBCT program with training in mindfulness strategies for 8 weeks. The adapted MBCT intervention will consist of eight weekly group sessions of 1 hour and 30 minutes, led by a certified instructor, to address the symptoms in the university population. In addition, complemented with the inclusion of audiovisual material, aimed at guiding self-applied daily exercises.
Study: NCT06044025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Subjects will start with metformin 500 mg by mouth (po) two times daily (bid) with meals for 14 days. Metformin titration will then increase to 850 milligram (mg) po bid for 14 days before increasing titration to a desired dosage of 1,000 mg po bid. For those subjects currently taking Metformin, they will continue current dose (if 1,000 mg po bid) or titrate dose as just described until maximum dose is achieved.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Turmeric
Description: Each subject will start with 1,500 mg turmeric po daily with meals. The dose can be temporarily reduced to 1,000 mg po daily for those who report GI discomfort. If GI discomfort has resolved within one month of the dose reduction, subjects will resume 1,500 mg po daily. If GI discomfort has not resolved or resumes at increased dose, the subject may be instructed to stop taking the study treatment and removed from the study.
Study: NCT05389098

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand-Eating
Description: eat-hands type food mode

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Usual eating mode
Study: NCT05101447

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: At baseline, subjects will be randomized 1:1 to one of two treatment arms: the current standard of clinical care \[MMFBSA: 600 mg/m2/dose; max: 3 gram/day\] or pharmacokinetically-driven precision dosing \[MMFPK: 12-hour target area under the exposure curve of MPA (MPA-AUC0-12) at 60 mg\*h/L\].

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: At baseline, subjects will be randomized 1:1 to one of two treatment arms: the current standard of clinical care \[MMFBSA: 600 mg/m2/dose; max: 3 gram/day\] or pharmacokinetically-driven precision dosing \[MMFPK: 12-hour target area under the exposure curve of MPA (MPA-AUC0-12) at 60 mg\*h/L\].
Study: NCT05106127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EG-007
Description: A Repurposed Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EG-007
Description: A Repurposed Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EG-007
Description: A Repurposed Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 100 mg/4 mL (25 mg/ml) Injection
Description: Pembrolizumab will be provided as a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution that requires dilution for intravenous infusion. Each vial contains 100 mg of pembrolizumab in 4 mL of solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 100 mg/4 mL (25 mg/ml) Injection
Description: Pembrolizumab will be provided as a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution that requires dilution for intravenous infusion. Each vial contains 100 mg of pembrolizumab in 4 mL of solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 100 mg/4 mL (25 mg/ml) Injection
Description: Pembrolizumab will be provided as a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution that requires dilution for intravenous infusion. Each vial contains 100 mg of pembrolizumab in 4 mL of solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Capsules
Description: Lenvatinib will be provided as 4-mg and 10-mg capsules. Lenvatinib is formulated with calcium carbonate, mannitol, microcrystalline cellulose, hydroxypropyl cellulose, low-substituted hydroxypropylcellulose, and talc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Capsules
Description: Lenvatinib will be provided as 4-mg and 10-mg capsules. Lenvatinib is formulated with calcium carbonate, mannitol, microcrystalline cellulose, hydroxypropyl cellulose, low-substituted hydroxypropylcellulose, and talc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Capsules
Description: Lenvatinib will be provided as 4-mg and 10-mg capsules. Lenvatinib is formulated with calcium carbonate, mannitol, microcrystalline cellulose, hydroxypropyl cellulose, low-substituted hydroxypropylcellulose, and talc.
Study: NCT04802330

Intervention type: OTHER
Intervention: Questionnaire
Description: Assessment of causes of FGM Beni Suef localities. 3. Explore the relationship between some of the social and demographic variables such as age, education, place of residence, marital status, religion and economic level and practice of FGM.
Study: NCT04867928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax+azacitidine
Description: subjects will receive venetoclax 400 mg orally QD on Days 1 - 28 plus azacitidine 75 mg/m2 SC or IV daily for 7 days. Cycle Length - 28 Days. . Subjects will continue treatment until subsequent alloSCT.